We explore the discovery of GLP-1, its evolution into todays leading therapies for diabetes and obesity, and the molecular and clinical mechanisms that drive their success
Use this feedback to decide if you should continue, adjust your dose, or try a different approach
Phase 2 first patient dosed January 2026, and the Phase 1 readout showed up to ~10% weight loss in four weeks in individual patients on a long-acting PK profile
We start by assessing your medical history, body composition, and lifestyle habits
Insurance is not required for our 8 Week Semaglutide Weight Loss Program
As Nicholas Florko wrote in the Atlantic , America has a new GLP-1 playbook, with a shot to lose weight and a pill to keep it off